Grice S, Olsson-Brown A, Naisbitt D, Hammond S
Chem Res Toxicol. 2024; 37(7):1086-1103.
PMID: 38912648
PMC: 11256900.
DOI: 10.1021/acs.chemrestox.4c00067.
Ohno H, Hayashi T, Torii S, Niwa M, Katagiri N, Nakao Y
Cancers (Basel). 2024; 16(11).
PMID: 38893195
PMC: 11171386.
DOI: 10.3390/cancers16112076.
Yan D
Biomedicines. 2023; 11(11).
PMID: 38001917
PMC: 10669068.
DOI: 10.3390/biomedicines11112916.
Kalra A, Rashdan S
Front Oncol. 2023; 13:1158417.
PMID: 37124513
PMC: 10140561.
DOI: 10.3389/fonc.2023.1158417.
Wakasaki T, Manako T, Yasumatsu R, Hara H, Toh S, Masuda M
PLoS One. 2022; 17(7):e0271907.
PMID: 35901098
PMC: 9333293.
DOI: 10.1371/journal.pone.0271907.
Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.
Liao D, Yu L, Shangguan D, Zhang Y, Xiao B, Liu N
Front Pharmacol. 2022; 13:905947.
PMID: 35734411
PMC: 9207473.
DOI: 10.3389/fphar.2022.905947.
Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Chan D, Choi H, Lee V
Cancers (Basel). 2022; 14(9).
PMID: 35565285
PMC: 9102470.
DOI: 10.3390/cancers14092157.
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K
Clin Cancer Res. 2021; 28(5):893-902.
PMID: 34921023
PMC: 9397372.
DOI: 10.1158/1078-0432.CCR-21-3194.
Risk factors for immune-related adverse events: what have we learned and what lies ahead?.
Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M
Biomark Res. 2021; 9(1):79.
PMID: 34732257
PMC: 8565046.
DOI: 10.1186/s40364-021-00314-8.
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.
Zhai X, Liu J, Liang Z, Li Z, Liu Y, Huang L
Front Oncol. 2021; 11:661034.
PMID: 34249697
PMC: 8264361.
DOI: 10.3389/fonc.2021.661034.
Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure.
Kaira K, Kobayashi K, Shiono A, Yamaguchi O, Hashimoto K, Mouri A
Thorac Cancer. 2021; 12(6):864-873.
PMID: 33522139
PMC: 7952801.
DOI: 10.1111/1759-7714.13864.
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
Saito Y, Sasaki S, Oikado K, Tominaga J, Sata M, Sakai F
Cancer Sci. 2020; 112(4):1495-1505.
PMID: 33098725
PMC: 8019215.
DOI: 10.1111/cas.14710.
Identification of Clonal Neoantigens Derived From Driver Mutations in an -Mutated Lung Cancer Patient Benefitting From Anti-PD-1.
Wu D, Liu Y, Li X, Liu Y, Yang Q, Liu Y
Front Immunol. 2020; 11:1366.
PMID: 32793190
PMC: 7390822.
DOI: 10.3389/fimmu.2020.01366.
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with Rearrangement.
Oya Y, Kuroda H, Nakada T, Takahashi Y, Sakakura N, Hida T
Int J Mol Sci. 2020; 21(7).
PMID: 32283823
PMC: 7178012.
DOI: 10.3390/ijms21072623.
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R
Thorac Cancer. 2020; 11(4):935-942.
PMID: 32129931
PMC: 7113046.
DOI: 10.1111/1759-7714.13378.
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O, Kaira K, Kawasaki T, Mouri A, Hashimoto K, Shiono A
Thorac Cancer. 2020; 11(4):1045-1051.
PMID: 32068351
PMC: 7113047.
DOI: 10.1111/1759-7714.13363.
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Park H, Sholl L, Hatabu H, Awad M, Nishino M
Radiology. 2019; 293(1):15-29.
PMID: 31385753
PMC: 6776234.
DOI: 10.1148/radiol.2019190173.
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y
Thorac Cancer. 2019; 10(4):975-979.
PMID: 30864291
PMC: 6449223.
DOI: 10.1111/1759-7714.13039.
Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence.
Chen P, Chen F, Lei J, Zhou B
Onco Targets Ther. 2018; 11:9033-9047.
PMID: 30588016
PMC: 6296202.
DOI: 10.2147/OTT.S182077.
Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.
Nishino M, Hatabu H, Sholl L, Ramaiya N
Radiographics. 2017; 37(5):1371-1387.
PMID: 28898185
PMC: 5621730.
DOI: 10.1148/rg.2017170015.
